Treatment Access News
INESSS now in year 2 of firbrosis requirements scale-back
march 28, 2016
The Institut national d’excellence en santé et en services sociaux (INESSS) in Quebec is now in its second year of implementing a scale-back of fibrosis requirements for people living with chronic hepatitis C. This means that the reimbursement criteria in Quebec is now a fribrosis score of F1 if there are poor prognosis factors, F2/F3 otherwise. Previously the requirements were F3/F4 without consideration for poor prognosis factors.
INESSS identifies “poor prognosis factors” as the below:
- · organ transplantation (pre- or post-transplantation);
· severe extra-hepatic manifestations of hepatitis C (e.g. type II or III mixed cryoglobulinemia with damage to the organs, vasculitis, nephropathy, B-cell non-Hodgkin's lymphoma);
· HIV or HBV co-infection;
· other liver disease (e.g. nonalcoholic steatohepatitis);
· type-2 diabetes;
· porphyria cutanea tarda.
HIV/HCV co-infection is a poor prognosis factor that may hasten access to HCV meds.
Read the expanded reimbursement criteria here.